US Patent Issued to Georgia Tech Research on Sept. 1 for "In situ thiol-maleimide crosslinked hydrogel for immune checkpoint blockade delivery" (Georgia Inventors)

ALEXANDRIA, Va., Sept. 1 -- United States Patent no. 12,723,081, issued on Sept. 1, was assigned to Georgia Tech Research Corp. (Atlanta).

"In situ thiol-maleimide crosslinked hydrogel for immune checkpoint blockade delivery" was invented by Susan Napier Thomas (Atlanta) and Jihoon Kim (Atlanta).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are hydrogel compositions that can be used to deliver therapeutic agents, including therapeutic proteins, to patients in need thereof. In an embodiment, the therapeutic agent is an immune checkpoint blockade antibody, and the hydrogel is a thermoresponsive polymer crosslinked with a hydrophilic polymer."

The patent was filed on July 13, 2021, under Application ...